Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Immix Biopharma, Inc. Common Stock Frequently Asked Questions
What is the ticker symbol for Immix Biopharma, Inc. Common Stock? What does IMMX stand for in stocks?
IMMX is the stock ticker symbol of Immix Biopharma, Inc. Common Stock. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Immix Biopharma, Inc. Common Stock (IMMX)?
As of Fri Dec 20 2024, market cap of Immix Biopharma, Inc. Common Stock is 59.69 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of IMMX stock?
You can check IMMX's fair value in chart for subscribers.
Is Immix Biopharma, Inc. Common Stock a good stock to buy?
The fair value guage provides a quick view whether IMMX is over valued or under valued. Whether Immix Biopharma, Inc. Common Stock is cheap or expensive depends on the assumptions which impact Immix Biopharma, Inc. Common Stock's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IMMX.